Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series

Title: Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series

Volume: 6 Issue: 1

Author(s): Julian Norman Kenyon and Richard James Fuller

Affiliation:

Keywords: Sonodynamic therapy, photodynamic therapy, immunoediting, cancer, ultrasound, photosensitiser, malignant pathologies, tetra pyrrole, porphyrin ring, energy, molecular oxygen, cell necrosis, cytotoxicity, absorption, tissues, physiotherapy, safety, tumour growth, death, wavelengths, histology, Oncology, lymph nodes, T cell, lymphocyte division, radiotherapy, chemotherapy, photooxidative cytotoxic, neutrophilia, OZONE, AUTOHAEMOTHERAPY, TUMOUR HYPOXIA, infusion, oestrogen, progesterone, receptor, chest infections, X Ray, biopsy

Abstract: Sonodynamic Photodynamic Therapy (SPDT) is a novel cancer treatment approach using a photosensitive agent (Sonnelux-1) with reported ultrasound-activated properties. The sensitiser is administered prior to a cycle of light and low-intensity ultrasound exposure. Ultrasound has the advantage of significantly greater tissue penetrance compared to light, which potentially allows non-invasive activation of the sensitiser within deep-sited tumours. Sonnelux-1 has previously demonstrated significant tumour cell inhibition following ultrasound administration in animal studies, and several case reviews have been published reporting clinical benefits in metastatic cancer patients. This current case series presents outcome measures of five patients with a variety of cancer diagnoses following SPDT, providing further evidence of beneficial treatment outcomes.

Cite this article as:

Norman Kenyon Julian and James Fuller Richard, Outcome Measures Following Sonodynamic Photodynamic Therapy – A Case Series, Current Drug Therapy 2011; 6 (1) . https://dx.doi.org/10.2174/157488511794079059